Richard Brudnick has served as a member of our board of
directors since April 2023. Mr. Brudnick is the Chief
Business Officer at Prime Medicine. Prior to joining
Prime Medicine, he was Chief Business Officer and Head
of Strategy for Codiak BioSciences, a leader in the
field of exosome therapeutics. Before Codiak, Mr.
Brudnick was Executive Vice President of Business
Development and Alliance Management at Bioverativ, Inc.,
a company he helped found. Until Bioverativ’s
acquisition by Sanofi, he led business development
efforts to build a significant pipeline in rare blood
disorders. Mr. Brudnick joined Bioverativ at its
spin-off from Biogen where, over the course of nearly 15
years, he initiated, led and completed transactions that
led to several marketed products including Leqembi,
Tecfidera, Spinraza and its biosimilars joint venture
with Samsung. Mr. Brudnick also was CEO of a regional
pharmaceutical distribution business, which he sold to a
strategic buyer; co-founded two companies; and was a
strategy consultant at Bain & Company. Mr. Brudnick
holds an M.S. and B.S. in Management Science from
Massachusetts Institute of Technology Sloan School of
Management.
Richard Brudnick
Chief Business Officer, Prime Medicine